"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing of selexipag (Uptravi, Actelion Registration Ltd) for the treatment of adults with pulmonary arterial hypertension (PAH)./"...
Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of Kerlone (betaxolol hydrochloride) therapy without the physician's advice.
Although cardiac failure rarely occurs in appropriately selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult a physician at the first sign or symptom of failure.
Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness. Patients should contact their physician if any difficulty in breathing occurs, and before surgery of any type. Patients should inform their physicians, ophthalmologists, or dentists that they are taking Kerlone (betaxolol hydrochloride) . Patients with diabetes should be warned that beta-blockers may mask tachycardia occurring with hypoglycemia.
Last reviewed on RxList: 10/31/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Kerlone Information
Kerlone - User Reviews
Kerlone User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.